A Blog from Gerbsman Partners Board of Intellectual Capital on “Maximizing Enterprise Value” for technology, life science, medical device and cleantech companies and their Intellectual Property
Ron was a dear friend of over 50 years. He passed away this week from Parkinson’s disease.
Ron and I were “Masters of the Universe” in the 1970’s. We were both put in CFO and CEO positions to stabilize, restructure and turnaound a $250 million Data Services Division. Little did we know that this would be our first experiences as Crisis/Turnaround Managers. Ron was a great partner; focused, smart and had high ethics and integrity. We were a very successful team.
Over the years Ron and I worked together many times. He was a Turnaround CEO for a number of Life Science companies, where I worked with him on capital raising and debt financing and after that he began his career as an international Executive Search CEO, where he assisted the private equity and venture capital community.
Ron and his wife Lynn moved to Texas about 15 years ago to raise and jump horses. Although from Chicago, he became a Texan and loved Dallas.
Ron had this great smile – see below.
Ron and I talked once a week and it always put a smile on my face when he called and said “The Gerbs”,
His wife, Lynn, has been a saint taking care of Ron. She put off Chemo to take care of him at home. Lynn our condolences from our family.
Be at peace my friend, you are with “GOD” now.
With respect, with love for a friend and with admiration for the person.
Respectfully – “The Gerbs” and the Gerbsman family.
Successful ‘Date-Certain M&A’ of Stemedica Cell Technologies Inc., its Assets and Intellectual Property
Gerbsman Partners is pleased to announce the successful completion of maximizing the value of the Assets and Intellectual Properties at Stemedica Cell Technologies, Inc.
Due to market conditions and trends, the Board of Directors and senior lender made the strategic decision to maximize the value of its Assets and Intellectual properties.
Gerbsman Partners – led by Steven R. Gerbsman, Principal and Kenneth Hardesty (CEO in Residence)– provided the CEO with financial advisory leadership through its proprietary ‘Date-Certain M&A Process’, facilitated the sale of the company’s Assets and Intellectual Property and the closing of the sale with other company Advisors.
1. Business consulting and investment banking domain expertise in developing strategic action plans.
2. Implementing its proprietary ‘Date-Certain M&A Process’ in order to maximize value of Stemedica Assets and Intellectual properties.
3. “Managing and guiding the process” among potential acquirers, lawyers, advisors, as well as all stakeholders of interest.
About Gerbsman Partners
Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in underperforming, undercapitalized and undervalued companies and their intellectual properties. Since 2001, Gerbsman Partners has successfully maximized the values of 121 companies in a wide and diverse spectrum of industries, ranging from technology, medical device/life science, digital marketing to cyber security, to name only a few.*
In the process, GP has successfully restructured/terminated over $810 million of real estate executory contracts and equipment lease/sub-debt obligations, and has assisted in over $2.3 billion of financings, restructurings and M&A transactions.*
Gerbsman Partners has offices and strategic alliances in San Francisco, Orange County, Boston, New York, Washington DC, McLean, VA, Europe and Israel.
*For further information on Gerbsman Partners expertise and industry experience, please request our company profile here
of Pennington Biomedical Research Center in Baton Rouge, La. Credit: Pennington Biomedical Research Center
Pennington Biomedical Research Center’s Dr. Steven Heymsfield and Dr. Peter Katzmarzyk are among the most influential researchers in the world who demonstrate significant and broad influence in their fields, according to Clarivate Analytics’ 2024 List of Highly Cited Researchers.
This honor highlights researchers whose work has had significant global influence, as evidenced by their exceptional citation records in leading scientific publications. The 2024 Highly Cited Researchers hail from more than 1,200 institutions in 59 nations and regions.
The Highly Cited Researchers list, compiled annually by Clarivate Analytics, identifies scientists who are among the top 1 percent of researchers in their field, as measured by citations in the Web of Science database during the period from 2013 to 2023.
“Pennington Biomedical is home to all-star researchers known worldwide, and this recognition for Dr. Heymsfield and Dr. Katzmarzyk shows the impact they are having in the field of obesity and nutrition research,” said Dr. John Kirwan, Pennington Biomedical Executive Director. “We congratulate them both for this recognition and all of Louisiana and Baton Rouge can be proud that they are conducting their world-renowned research here at Pennington Biomedical.”
Dr. Heymsfield and Dr. Katzmarzyk are internationally recognized for their groundbreaking contributions to obesity research, physical activity, and public health.
Steven Heymsfield, M.D., Professor of Metabolism & Body Composition, has an h-index of 141. He is listed on 1,314 publications that have been cited close to 80,000 times. His most cited paper, “Epidemiology of sarcopenia among the elderly in New Mexico,” published in the American Journal of Epidemiology, has been cited more than 2,800 times.
“This achievement reflects not just individual recognition, but the incredible support and collaboration of everyone at Pennington Biomedical,” Dr. Heymsfield said. “Conducting impactful and high-quality research requires not only dedication but also access to outstanding facilities, resources, and a thriving scientific community—qualities exemplified at Pennington Biomedical. I am grateful to be part of an institution that fosters innovation and excellence in research, enabling us to address critical challenges in health and nutrition on a global scale.”
Peter Katzmarzyk, Ph.D., Associate Executive Director for Population and Public Health Sciences; Professor; and Marie Edana Corcoran Endowed Chair in Pediatric Obesity and Diabetes, has an h-index of 100. He is listed on 587 publications that have been cited more than 45,000 times. His paper, “Effect of Physical Inactivity on Major Non-Communicable Diseases Worldwide: An Analysis of Burden of Disease and Life Expectancy,” published in Lancet, has been cited more than 5,400 times.
“Being named among the world’s highly cited researchers is both an honor and a reflection of the impact our work is making on global health,” Katzmarzyk said. “This recognition underscores the importance of addressing critical issues like physical inactivity, obesity, and chronic disease to improve lives worldwide.”
The 2024 Highly Cited Researchers list features 3,560 Highly Cited Researcher awards in 20 fields, with an additional 3,326 recognitions for outstanding performance in multiple fields (cross-field).
“The Highly Cited Researchers list identifies and celebrates exceptional individual researchers at Pennington Biomedical whose significant and broad influence in their fields translates to impact in their research community. Their pioneering innovations contribute to a healthier, more sustainable and secure world. These researchers’ achievements strengthen the foundation of excellence and innovation that drives societal progress,” said David Pendlebury, Head of Research Analysis at the Institute for Scientific Information at Clarivate.
About the Pennington Biomedical Research Center
The Pennington Biomedical Research Center is at the forefront of medical discovery as it relates to understanding the triggers of obesity, diabetes, cardiovascular disease, cancer and dementia. Pennington Biomedical has the vision to lead the world in promoting metabolic health and eliminating metabolic disease through scientific discoveries that create solutions from cells to society. The center conducts basic, clinical, and population research, and is a campus in the LSU System.
The research enterprise at Pennington Biomedical includes over 530 employees within a network of 44 clinics and research laboratories, and 13 highly specialized core service facilities. Its scientists and physician/scientists are supported by research trainees, lab technicians, nurses, dietitians, and other support personnel. Pennington Biomedical is a globally recognized state-of-the-art research institution in Baton Rouge, Louisiana.
Dr. Steven Heymsfield and Dr. Peter Katzmarzyk Rank Among the World’s Most Influential Researcher
December 2nd, 2024
Dr. Steven Heymsfield and Dr. Peter Katzmarzyk of Pennington Biomedical Research Center in Baton Rouge, La. Credit: Pennington Biomedical Research Center
Pennington Biomedical Research Center’s Dr. Steven Heymsfield and Dr. Peter Katzmarzyk are among the most influential researchers in the world who demonstrate significant and broad influence in their fields, according to Clarivate Analytics’ 2024 List of Highly Cited Researchers.
This honor highlights researchers whose work has had significant global influence, as evidenced by their exceptional citation records in leading scientific publications. The 2024 Highly Cited Researchers hail from more than 1,200 institutions in 59 nations and regions.
The Highly Cited Researchers list, compiled annually by Clarivate Analytics, identifies scientists who are among the top 1 percent of researchers in their field, as measured by citations in the Web of Science database during the period from 2013 to 2023.
“Pennington Biomedical is home to all-star researchers known worldwide, and this recognition for Dr. Heymsfield and Dr. Katzmarzyk shows the impact they are having in the field of obesity and nutrition research,” said Dr. John Kirwan, Pennington Biomedical Executive Director. “We congratulate them both for this recognition and all of Louisiana and Baton Rouge can be proud that they are conducting their world-renowned research here at Pennington Biomedical.”
Dr. Heymsfield and Dr. Katzmarzyk are internationally recognized for their groundbreaking contributions to obesity research, physical activity, and public health.
Steven Heymsfield, M.D., Professor of Metabolism & Body Composition, has an h-index of 141. He is listed on 1,314 publications that have been cited close to 80,000 times. His most cited paper, “Epidemiology of sarcopenia among the elderly in New Mexico,” published in the American Journal of Epidemiology, has been cited more than 2,800 times.
“This achievement reflects not just individual recognition, but the incredible support and collaboration of everyone at Pennington Biomedical,” Dr. Heymsfield said. “Conducting impactful and high-quality research requires not only dedication but also access to outstanding facilities, resources, and a thriving scientific community—qualities exemplified at Pennington Biomedical. I am grateful to be part of an institution that fosters innovation and excellence in research, enabling us to address critical challenges in health and nutrition on a global scale.”
Peter Katzmarzyk, Ph.D., Associate Executive Director for Population and Public Health Sciences; Professor; and Marie Edana Corcoran Endowed Chair in Pediatric Obesity and Diabetes, has an h-index of 100. He is listed on 587 publications that have been cited more than 45,000 times. His paper, “Effect of Physical Inactivity on Major Non-Communicable Diseases Worldwide: An Analysis of Burden of Disease and Life Expectancy,” published in Lancet, has been cited more than 5,400 times.
“Being named among the world’s highly cited researchers is both an honor and a reflection of the impact our work is making on global health,” Katzmarzyk said. “This recognition underscores the importance of addressing critical issues like physical inactivity, obesity, and chronic disease to improve lives worldwide.”
The 2024 Highly Cited Researchers list features 3,560 Highly Cited Researcher awards in 20 fields, with an additional 3,326 recognitions for outstanding performance in multiple fields (cross-field).
“The Highly Cited Researchers list identifies and celebrates exceptional individual researchers at Pennington Biomedical whose significant and broad influence in their fields translates to impact in their research community. Their pioneering innovations contribute to a healthier, more sustainable and secure world. These researchers’ achievements strengthen the foundation of excellence and innovation that drives societal progress,” said David Pendlebury, Head of Research Analysis at the Institute for Scientific Information at Clarivate.
About the Pennington Biomedical Research Center
The Pennington Biomedical Research Center is at the forefront of medical discovery as it relates to understanding the triggers of obesity, diabetes, cardiovascular disease, cancer and dementia. Pennington Biomedical has the vision to lead the world in promoting metabolic health and eliminating metabolic disease through scientific discoveries that create solutions from cells to society. The center conducts basic, clinical, and population research, and is a campus in the LSU System.
The research enterprise at Pennington Biomedical includes over 530 employees within a network of 44 clinics and research laboratories, and 13 highly specialized core service facilities. Its scientists and physician/scientists are supported by research trainees, lab technicians, nurses, dietitians, and other support personnel. Pennington Biomedical is a globally recognized state-of-the-art research institution in Baton Rouge, Louisiana.
Several years ago Gerbsman Partners posted the photo “Keeping God’s Acre”; you may recall the photo of the eagle on the tombstone at Fort Snelling National Cemetery. The photo was posted to honor our Fallen Warriors during the Memorial Day holiday. Gerbsman Partners stated that the photo was taken on a June morning. Recently, the copyright holder, Jo “Blue” Edwards-Johns of Kansas, reached out and shared that the photo was actually taken during the spring of 2011. we apologize for any confusion this may have caused. Gerbsman Partners still believes that the photo should become an official graphic for Memorial Day, 4th of July and I or Veterans Day given the powerful imagery it evokes. A link to the copyrighted photo Keeping God’s Acre on Facebook page can be found:
As we begin Veterans Day/Week 2024, we say “Thank You” to the men and woman of our armed services and suggest that it is time for all to “step up” and find ways to support our Veterans. To often we say “thank you for your service” and then do nothing more. Please think about supporting various Veterans groups with donations, food, clothing and moral support. The have “Earned” it and we “Owe” it to them.
In the late summer of 1967, I was on my way back to Basic Training at Fort Dix, N.J. I was in New York City and an older couple came up to me and said “Thank You” for serving and then gave me $ 20 to enjoy a dinner on them. The gentleman said he served in the Korean War and understands and appreciates what men and woman in uniform go through. I said thank you, enjoyed a great dinner and to this day, remember their kind gesture.On this Veterans Day/Week, our family will support the Wounded Warriors program.
On 11/11/24, I will also continue to remember that couple and honor them by buying dinner for soldiers in uniform. I will ask them to do the same thing, 5, 10, 20 and 40 years later.
May God Bless our troops and provide our leaders with the courage and strength to do what is Right and what is Just.Please always remember – FREEDOM IS NOT FREE
What are YOU doing to HELP?
And to the memory of my father, Sgt. George Gerbsman, my uncles Ben Gerbsman and Bob Chapnick who served in the Navy and Cpt. Gilbert Falk, all WW11 veterans.
of Pennington Biomedical Research Center in Baton Rouge, La. Credit: Pennington Biomedical Research Center
Blog of Intellectual Capital 
